Advertisement

Current Urology Reports

, 20:4 | Cite as

Renal Medullary Carcinoma: a Report of the Current Literature

  • Leandro Blas
  • Javier RobertiEmail author
  • Jorgelina Petroni
  • Liliana Reniero
  • Federico Cicora
Kidney Diseases (G Ciancio, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Kidney Diseases

Abstract

Purpose of the Review

We present an updated report of renal medullary carcinoma (RMC), a rare and aggressive condition.

Recent Findings

There is a majority of male patients, of African descent, in the second or third decade of life. In differential diagnosis, other tumors, such as malignant rhabdoid tumor (MRT), vinculin-anaplastic lymphoma kinase (VCL-ALK) translocation renal cell carcinoma, and collecting duct carcinoma, may present difficulties. Abnormalities of tumor suppressor gene SMARCB1 have been found in RMC. Reported symptoms were hematuria, pain, weight loss, respiratory distress, palpable mass, cough, and fever. Most patients present with metastases at diagnosis. There is no definite recommended treatment, and protocols are extrapolated from other malignancies, with nephrectomy and systemic therapies being most frequently used. Response to treatment and prognosis remain very poor.

Summary

RMC is a rare and aggressive tumor. Definitive diagnosis requires histological assessment and the presence of sickle-cell hemoglobinopathies.

Keywords

Renal medullary carcinoma Kidney cancer Sickle cell 

Notes

Compliance with Ethical Standards

Conflict of Interest

Leandro Blas, Javier Roberti, Jorgelina Petroni, Liliana Reniero, and Federico Cicora each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lee JS, Sanchez TR, Wootton-Gorges S. Malignant renal tumors in children. J Kidney Cancer VHL. 2015;2(3):84–9.  https://doi.org/10.15586/jkcvhl.2015.29.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    •• Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017;120(6):782–92.  https://doi.org/10.1111/bju.13705 Large and Current Case Series of RMC.CrossRefPubMedGoogle Scholar
  3. 3.
    • Davis C, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11 First report of the condition.CrossRefGoogle Scholar
  4. 4.
    Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer. 2015;62(10):1694–9.  https://doi.org/10.1002/pbc.25592.CrossRefPubMedGoogle Scholar
  5. 5.
    Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798–805.  https://doi.org/10.1016/j.eururo.2005.11.035.CrossRefPubMedGoogle Scholar
  6. 6.
    Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, et al. Renal medullary carcinoma: establishing standards in practice. J Oncol Pract. 2017;13(7):414–21.  https://doi.org/10.1200/JOP.2017.020909.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Di Stefano RF, Buttigliero C, De Luca E, Reale ML, Pisano C, Leone G, et al. Metastatic renal medullary carcinoma treated with immune checkpoint inhibitor: case report and literature review. Clin Genitourin Cancer. 2018.  https://doi.org/10.1016/j.clgc.2018.07.011.
  8. 8.
    Carden MA, Perdahl-Wallace E, Greenberg J, McCarty JM. Autologous stem-cell transplant for metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2018;65(9):e27267.  https://doi.org/10.1002/pbc.27267.CrossRefPubMedGoogle Scholar
  9. 9.
    Lai JZ, Lai HH, Cao D. Renal cell carcinoma, unclassified with medullary phenotype and synchronous renal clear cell carcinoma present in a patient with no sickle cell trait/disease: diagnostic and therapeutic challenges. Anticancer Res. 2018;38(6):3757–61.  https://doi.org/10.21873/anticanres.12657.CrossRefPubMedGoogle Scholar
  10. 10.
    Goenaga-Vazquez Y, Colon G, Barrios N, Correa M. Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition. CEN Case Rep. 2018;7(1):121–6.  https://doi.org/10.1007/s13730-018-0308-3.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ahmad HR, Faruk JA, Bugaje MA, Solomon A, Samaila MOA, Akuse RM. Sarcomatoid renal cell carcinoma in an adolescent with sickle cell anaemia. Case Rep Oncol Med. 2017;2017:2129450.  https://doi.org/10.1155/2017/2129450.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Heng DYC. Renal medullary carcinoma. J Oncol Pract. 2017;13(7):422–3.  https://doi.org/10.1200/jop.2017.023812.CrossRefPubMedGoogle Scholar
  13. 13.
    Ibilibor C, Medway A, Nelius T. Renal medullary carcinoma with an ophthalmic metastasis. Urol Ann. 2017;9(2):184–7.  https://doi.org/10.4103/0974-7796.204184.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Caliskan S, Gokce AM, Gumrukcu G, Onenerk M. Renal medullary carcinoma; a rare entity. Iran J Med Sci. 2017;42(2):215–8.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, et al. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. J Immunother Cancer. 2017;5:1.  https://doi.org/10.1186/s40425-016-0206-1.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kalavar MR, Ali S, Safarpour D, Kunnakkat SD. Renal medullary carcinoma with an aggressive clinical course: a case report and review of the literature. Case Rep Oncol. 2017;10(1):1–7.  https://doi.org/10.1159/000455007.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Colombo P, Smith SC, Massa S, Renne SL, Brambilla S, Peschechera R, et al. Unclassified renal cell carcinoma with medullary phenotype versus renal medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait. Urol Case Rep. 2015;3(6):215–8.  https://doi.org/10.1016/j.eucr.2015.07.011.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Batra S. Is there a role for antiangiogenic therapy in renal medullary carcinoma? Pediatr Blood Cancer. 2016;63(4):746–7.  https://doi.org/10.1002/pbc.25832.CrossRefPubMedGoogle Scholar
  19. 19.
    Rabener MJ, Howell C. Chest discomfort in a patient with cancer. JAAPA: Official Journal of the American Academy of Physician Assistants. 2015;28(6):43–4, 466.  https://doi.org/10.1097/01.JAA.0000464279.28870.3b.CrossRefGoogle Scholar
  20. 20.
    Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, et al. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression. Cancer Biol Ther. 2015;16(1):28–33.  https://doi.org/10.4161/15384047.2014.972843.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Mast Vilaseca R, Pons EA. Renal medullary carcinoma in a young white adult without sickle cell trait or disease. Australas Radiol. 2015;57(4):361–3.  https://doi.org/10.1016/j.rx.2014.09.003.CrossRefGoogle Scholar
  22. 22.
    Levi Sandri GB, Spoletini G, Lai Q, Mennini G, Rossi M. Cystic presentation of a renal medullary carcinoma in a young woman. Urologia. 2015;82(2):124–6.  https://doi.org/10.5301/uro.5000097.CrossRefPubMedGoogle Scholar
  23. 23.
    Tripathy K, Misra A, Dash K. Cytodiagnosis of renal medullary carcinoma: report of a case with immunocytochemistry. Cytopathology. 2015;26(5):328–30.  https://doi.org/10.1111/cyt.12225.CrossRefPubMedGoogle Scholar
  24. 24.
    Amjad AI, Ali H, Appleman LJ, Maranchie J, Jackman S, Parwani A, et al. Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Case Rep Oncol Med. 2014;2014:615895.  https://doi.org/10.1155/2014/615895.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Shetty A, Matrana MR. Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J. 2014;14(2):270–5.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Daher P, Bourgi A, Riachy E, Khoury A, Rehayem C, Sader-Ghorra C. Renal medullary carcinoma in a white adolescent with sickle cell trait. J Pediatr Hematol Oncol. 2014;36(5):e285–9.  https://doi.org/10.1097/mph.0000000000000118.CrossRefPubMedGoogle Scholar
  27. 27.
    Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park, NY). 2013;27(9):893, 6, 8.Google Scholar
  28. 28.
    Maroja Silvino MC, Venchiarutti Moniz CM, Munhoz Piotto GH, Siqueira S, Galapo Kann A, Dzik C. Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil. Rare Tumors. 2013;5(3):e44.  https://doi.org/10.4081/rt.2013.e44.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Marsh A, Golden C, Hoppe C, Quirolo K, Vichinsky E. Renal medullary carcinoma in an adolescent with sickle cell anemia. Pediatr Blood Cancer. 2014;61(3):567.  https://doi.org/10.1002/pbc.24795.CrossRefPubMedGoogle Scholar
  30. 30.
    Anne M, Sammartino D, Chaudhary S, Bhuiya T, Mehrotra B. Renal medullary carcinoma masquerading as bilateral breast carcinoma category: case report. World J Oncol. 2013;4(3):169–72.  https://doi.org/10.4021/wjon676w.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sodji Q, Klein K, Sravan K, Parikh J. Predictive role of PD-L1 expression in the response of renal medullary carcinoma to PD-1 inhibition. J Immunother Cancer. 2017;5(1):62.  https://doi.org/10.1186/s40425-017-0267-9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Carter SA, Walker AN. Renal medullary carcinoma and sickle cell trait: a push for early diagnosis and intervention report of two cases. J Natl Med Assoc. 2017;109(1):63–5.  https://doi.org/10.1016/j.jnma.2016.08.006.CrossRefPubMedGoogle Scholar
  33. 33.
    Carden MA, Smith S, Meany H, Yin H, Alazraki A, Rapkin LB. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases. Pediatr Blood Cancer. 2017;64(7).  https://doi.org/10.1002/pbc.26402.
  34. 34.
    Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 2013;37(3):368–74.CrossRefGoogle Scholar
  35. 35.
    Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, et al. Characterization of adolescent and pediatric renal cell carcinoma: a report from the children's oncology group study AREN03B2. Cancer. 2015;121(14):2457–64.  https://doi.org/10.1002/cncr.29368.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Shi Z, Zhuang Q, You R, Li Y, Li J, Cao D. Clinical and computed tomography imaging features of renal medullary carcinoma: a report of six cases. Oncol Lett. 2016;11(1):261–6.  https://doi.org/10.3892/ol.2015.3891.CrossRefPubMedGoogle Scholar
  37. 37.
    Sandberg JK, Mullen EA, Cajaiba MM, Smith EA, Servaes S, Perlman EJ, et al. Imaging of renal medullary carcinoma in children and young adults: a report from the children's oncology group. Pediatr Radiol. 2017;47(12):1615–21.  https://doi.org/10.1007/s00247-017-3926-6.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Carlo MI, Chaim J, Patil S, Kemel Y, Schram AM, Woo K, et al. Genomic characterization of renal medullary carcinoma and treatment outcomes. Clin Genitourin Cancer. 2017;15(6):e987–e94.  https://doi.org/10.1016/j.clgc.2017.04.012.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    •• Ezekian B, Englum B, Gilmore BF, Nag UP, Kim J, Leraas HJ et al. Renal medullary carcinoma: a national analysis of 159 patients. Pediatr Blood Cancer. 2017;64(11).  https://doi.org/10.1002/pbc.26609. Large national analysis of RMC patients.
  40. 40.
    Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42(3):279–92.  https://doi.org/10.1097/pas.0000000000001000.CrossRefPubMedGoogle Scholar
  41. 41.
    Gebreselassie S, Simmons MN, Montague DK. Genitourinary manifestations of sickle cell disease. Cleve Clin J Med. 2015;82(10):679–83.  https://doi.org/10.3949/ccjm.82a.14029.CrossRefPubMedGoogle Scholar
  42. 42.
    Pawel BR. SMARCB1-deficient tumors of childhood: a practical guide. Pediatr Dev Pathol. 2018;21(1):6–28.  https://doi.org/10.1177/1093526617749671.CrossRefPubMedGoogle Scholar
  43. 43.
    Jarzembowski JA. Pediatric renal and genitourinary tract tumors and the contributions of Dr. Louis "Pepper" Dehner therewith. Semin Diagn Pathol. 2016;33(6):419–26.  https://doi.org/10.1053/j.semdp.2016.08.005.CrossRefPubMedGoogle Scholar
  44. 44.
    Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv Anat Pathol. 2014;21(6):394–410.  https://doi.org/10.1097/PAP.0000000000000038.CrossRefPubMedGoogle Scholar
  45. 45.
    Fleming S. Distal nephron neoplasms. Semin Diagn Pathol. 2015;32(2):114–23.  https://doi.org/10.1053/j.semdp.2015.02.004.CrossRefPubMedGoogle Scholar
  46. 46.
    Chung EM, Lattin GE Jr, Fagen KE, Kim AM, Pavio MA, Fehringer AJ, et al. Renal tumors of childhood: radiologic-pathologic correlation part 2. The 2nd decade: from the radiologic pathology archives. Radiographics. 2017;37(5):1538–58.  https://doi.org/10.1148/rg.2017160189.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Anazoeze M, Najibah G, Garba U, Shehu A, Florence F, Abdulaziz H, et al. Is renal medullary carcinoma the seventh nephropathy in sickle cell disease? A multi-center Nigerian survey. Afr Health Sci. 2016;16(2):490–6.  https://doi.org/10.4314/ahs.v16i2.17.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kalimuthu SN, Chetty R. Gene of the month: SMARCB1. J Clin Pathol. 2016;69(6):484–9.  https://doi.org/10.1136/jclinpath-2016-203650.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    • Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas. Eur Urol. 2016;69(6):1055–61.  https://doi.org/10.1016/j.eururo.2015.09.027 Paper on the explanatory model of genetic abnormalities in RMC. CrossRefPubMedGoogle Scholar
  50. 50.
    • Msaouel P, Tannir NM, Walker CL. A model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma. Clin Cancer Res. 2018;24(9):2044–9.  https://doi.org/10.1158/1078-0432.Ccr-17-3296 Proposed model on RMC. CrossRefPubMedGoogle Scholar
  51. 51.
    Amin MB, Smith SC, Agaimy A, Argani P, Compérat EM, Delahunt B, et al. Collecting duct carcinoma versus renal medullary carcinoma. Am J Surg Pathol. 2014;38(7):871–4.  https://doi.org/10.1097/pas.0000000000000222.CrossRefPubMedGoogle Scholar
  52. 52.
    Seo AN, Yoon G, Ro JY. Clinicopathologic and molecular pathology of collecting duct carcinoma and related renal cell carcinomas. Adv Anat Pathol. 2017;24(2):65–77.  https://doi.org/10.1097/PAP.0000000000000138.CrossRefPubMedGoogle Scholar
  53. 53.
    Gupta S, Kang HC, Ganeshan DM, Bathala TK, Kundra V. Diagnostic approach to hereditary renal cell carcinoma. AJR Am J Roentgenol. 2015;204(5):1031–41.  https://doi.org/10.2214/AJR.14.13514.CrossRefPubMedGoogle Scholar
  54. 54.
    Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015;9(3–4):E172–7.  https://doi.org/10.5489/cuaj.2373.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Leandro Blas
    • 1
    • 2
  • Javier Roberti
    • 1
    Email author
  • Jorgelina Petroni
    • 1
  • Liliana Reniero
    • 1
  • Federico Cicora
    • 1
  1. 1.FINAER (Foundation for Research and Assistance in Kidney Disease)Buenos AiresArgentina
  2. 2.Urology DepartmentHospital AlemánBuenos AiresArgentina

Personalised recommendations